Athithi Verma
QuickAccess read/Market Access/Pricing & Reimbursement New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days Athithi Verma· 20 October 2026· 2 min read· Synopulse The Institute for Clinical and Economic Review and West Health said on 20 October that the … Read more
Britain is paying to fix the front of the dementia pathway, and a blood test is the commercial prize among the nine projects.
Merck KGaA paid an 82% premium for one asset and a new therapy area, pricing divesiran’s Phase 2 effect as close to settled.
Lilly is buying options on delivery beyond the liver, paying little upfront until an AI-designed lipid proves it works.
Europe now has a daily achondroplasia injection on the market, a weekly one recommended, and an oral drug planning to file.
A guideline listing is the first thing a payer asks a device maker for, and Neuromod’s Lenire now has one in tinnitus.
The gap over Skyrizi widened from week 12 to week 24, the stronger signal in an open-label study without placebo.
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
Roche is paying platform money for ADCs that do not exist yet, five times what it paid Hansoh for a clinical asset in 2025.
NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin Athithi Verma·19 October 2026·11 min read·Synopulse NeuroPulseDeep pine banner. A violet neural network of neurons and synapses fills the right side, with a gold signal pulse firing along a chain of neurons, beside the NeuroPulse wordmark under the Synopulse and The … Read more